Cross-tumoral Phase 2 clinical trial exploring Crizotinib (PF-02341066) in patients with advanced tumours induced by causal alterations of either ALK or MET.

Trial Profile

Cross-tumoral Phase 2 clinical trial exploring Crizotinib (PF-02341066) in patients with advanced tumours induced by causal alterations of either ALK or MET.

Active, no longer recruiting
Phase of Trial: Phase II

Latest Information Update: 05 Dec 2017

At a glance

  • Drugs Crizotinib (Primary)
  • Indications Alveolar soft part sarcoma; Anaplastic large cell lymphoma; Clear cell sarcoma; Muscle tissue neoplasms; Renal cancer; Rhabdomyosarcoma
  • Focus Therapeutic Use
  • Acronyms CREATE
  • Most Recent Events

    • 05 Dec 2017 Results assessing the efficacy and safety of the tyrosine kinase inhibitor(TKI) crizotinib in patients with advanced or metastatic ASPS, were published in the Annals of Oncology.
    • 14 Nov 2017 Results (n=23) of cohort of patients with papillary renal cell carcinoma assessing disease control activity, published in the European Journal of Cancer.
    • 07 Nov 2017 Planned primary completion date changed from 1 Dec 2017 to 1 Nov 2017.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top